Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Globenewswire
- Leadership Change: Jasper Therapeutics has appointed Jeet Mahal as CEO, succeeding Ronald Martell, who joined in 2022; Mahal brings over 30 years of life sciences experience and will drive the development of briquilimab, enhancing the company's competitiveness in chronic urticaria.
- Clinical Research Update: Jasper will host an investor webinar on January 8, 2026, to present updated data from the BEACON study and open-label extension studies, aiming to boost investor confidence and increase focus on briquilimab.
- Product Development Strategy: Mahal emphasized briquilimab's potential in chronic spontaneous urticaria and inducible urticaria, planning to efficiently complete current studies and lay the groundwork for future development, which is expected to provide more effective treatment options for patients.
- Former CEO Contributions: Ronald Martell successfully pivoted briquilimab's development towards allergic and immunological diseases during his tenure, establishing a foundation for clinical proof of concept that supports the company's future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JSPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JSPR
Wall Street analysts forecast JSPR stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.873
Low
4.00
Averages
12.00
High
20.00
Current: 0.873
Low
4.00
Averages
12.00
High
20.00
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jasper Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Jasper Therapeutics reported a Q1 GAAP EPS of -$0.04, beating market expectations by $0.48, indicating potential improvement in the company's financial performance.
- Cash Reserves Status: As of March 31, 2026, the company had cash and cash equivalents totaling $14.1 million, providing crucial funding support for future R&D and operations.
- R&D Expense Analysis: The research and development expense for Q1 2026 was $5.8 million, demonstrating the company's ongoing commitment to innovation and product development aimed at driving future growth.
- Administrative Expense Overview: The general and administrative expenses for Q1 amounted to $5.1 million, reflecting the company's operational management costs, which need to be monitored for their impact on overall profitability.
See More
Jasper Therapeutics Q4 Earnings Beat Expectations with Significant Cash Reserves
- Earnings Highlights: Jasper Therapeutics reported a Q4 GAAP EPS of -$0.32, beating market expectations by $0.48, indicating an improvement in financial performance that may boost investor confidence.
- Cash Reserves: As of December 31, 2025, Jasper Therapeutics had cash and cash equivalents totaling $28.7 million, providing ample funding for future R&D and operations, thereby enhancing its financial stability.
- New CEO Appointment: The recent appointment of a new CEO at Jasper Therapeutics is expected to bring a fresh strategic direction and management style, potentially driving growth in the competitive biopharmaceutical market.
- Research Data Update: The company updated data from its BEACON and open-label extension studies in chronic urticaria, demonstrating its ongoing efforts in the treatment space and potential market opportunities that may attract more investor interest.
See More
Jasper Therapeutics Reports Fiscal Year 2025 Results and Corporate Update
- Clinical Data Highlights: Jasper Therapeutics reported that 67% of patients in the BEACON study for chronic spontaneous urticaria achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points, indicating briquilimab's significant efficacy and potential to increase market share in this area.
- Financial Performance: As of December 31, 2025, Jasper's cash and cash equivalents totaled $28.7 million, while R&D expenses reached $11.4 million, resulting in a net loss of $75.8 million for the fiscal year 2025, highlighting financial pressures that may impact future clinical trial progress.
- Management Changes: Jeet Mahal was appointed as CEO to lead the company into a new phase of clinical growth, indicating a significant strategic shift that could influence investor confidence moving forward.
- Future Outlook: Jasper plans to initiate its Phase 2b/3 clinical trial for chronic spontaneous urticaria in the second half of 2026, although challenges related to capital availability remain; successful advancement could present new growth opportunities for the company.
See More
UBS Initiates Neutral Coverage on Jasper Therapeutics with $1.50 Target
- Coverage Initiation: UBS initiated coverage of Jasper Therapeutics (NASDAQ:JSPR) on March 23, 2026, with a Neutral rating and a $1.50 price target, indicating a cautious outlook due to competitive pressures that may limit upside potential.
- Clinical Data Update: On January 8, 2026, Jasper reported updated data for briquilimab, revealing that 67% of patients achieved a complete response at 12 weeks, while 83% responded by week 3 after the initial dose, highlighting the therapy's promise in chronic spontaneous urticaria (CSU).
- Future Research Plans: The company plans to initiate a Phase 2b study for CSU in the second half of 2026, with BEACON and open-label extension data supporting dose selection, demonstrating positive progress in clinical development.
- Investment Outlook Analysis: While Jasper is viewed as a potential investment, UBS noted that certain AI stocks offer greater upside potential and lower downside risk, reflecting a shift in market preference towards more attractive investment options in the biotech sector.
See More
UBS Initiates Coverage of Jasper Therapeutics Inc with Neutral Rating and $1.50 Price Target
Company Overview: Jaspar Therapeutics is a biopharmaceutical company focused on developing innovative therapies.
Recent Coverage: The company has received neutral ratings in recent analyses, indicating a cautious outlook from analysts.
Target Price: Analysts have set a target price of $1.50 for Jaspar Therapeutics' stock.
Market Position: The neutral rating suggests that while there is potential, there are also risks that investors should consider.
See More
Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment
- Leadership Change: Jasper Therapeutics has appointed Jeet Mahal as CEO, succeeding Ronald Martell, who joined in 2022; Mahal brings over 30 years of life sciences experience and will drive the development of briquilimab, enhancing the company's competitiveness in chronic urticaria.
- Clinical Research Update: Jasper will host an investor webinar on January 8, 2026, to present updated data from the BEACON study and open-label extension studies, aiming to boost investor confidence and increase focus on briquilimab.
- Product Development Strategy: Mahal emphasized briquilimab's potential in chronic spontaneous urticaria and inducible urticaria, planning to efficiently complete current studies and lay the groundwork for future development, which is expected to provide more effective treatment options for patients.
- Former CEO Contributions: Ronald Martell successfully pivoted briquilimab's development towards allergic and immunological diseases during his tenure, establishing a foundation for clinical proof of concept that supports the company's future growth.
See More
Jasper Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Jasper Therapeutics reported a Q1 GAAP EPS of -$0.04, beating market expectations by $0.48, indicating potential improvement in the company's financial performance.
- Cash Reserves Status: As of March 31, 2026, the company had cash and cash equivalents totaling $14.1 million, providing crucial funding support for future R&D and operations.
- R&D Expense Analysis: The research and development expense for Q1 2026 was $5.8 million, demonstrating the company's ongoing commitment to innovation and product development aimed at driving future growth.
- Administrative Expense Overview: The general and administrative expenses for Q1 amounted to $5.1 million, reflecting the company's operational management costs, which need to be monitored for their impact on overall profitability.
See More
Jasper Therapeutics Q4 Earnings Beat Expectations with Significant Cash Reserves
- Earnings Highlights: Jasper Therapeutics reported a Q4 GAAP EPS of -$0.32, beating market expectations by $0.48, indicating an improvement in financial performance that may boost investor confidence.
- Cash Reserves: As of December 31, 2025, Jasper Therapeutics had cash and cash equivalents totaling $28.7 million, providing ample funding for future R&D and operations, thereby enhancing its financial stability.
- New CEO Appointment: The recent appointment of a new CEO at Jasper Therapeutics is expected to bring a fresh strategic direction and management style, potentially driving growth in the competitive biopharmaceutical market.
- Research Data Update: The company updated data from its BEACON and open-label extension studies in chronic urticaria, demonstrating its ongoing efforts in the treatment space and potential market opportunities that may attract more investor interest.
See More
Jasper Therapeutics Reports Fiscal Year 2025 Results and Corporate Update
- Clinical Data Highlights: Jasper Therapeutics reported that 67% of patients in the BEACON study for chronic spontaneous urticaria achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points, indicating briquilimab's significant efficacy and potential to increase market share in this area.
- Financial Performance: As of December 31, 2025, Jasper's cash and cash equivalents totaled $28.7 million, while R&D expenses reached $11.4 million, resulting in a net loss of $75.8 million for the fiscal year 2025, highlighting financial pressures that may impact future clinical trial progress.
- Management Changes: Jeet Mahal was appointed as CEO to lead the company into a new phase of clinical growth, indicating a significant strategic shift that could influence investor confidence moving forward.
- Future Outlook: Jasper plans to initiate its Phase 2b/3 clinical trial for chronic spontaneous urticaria in the second half of 2026, although challenges related to capital availability remain; successful advancement could present new growth opportunities for the company.
See More
UBS Initiates Neutral Coverage on Jasper Therapeutics with $1.50 Target
- Coverage Initiation: UBS initiated coverage of Jasper Therapeutics (NASDAQ:JSPR) on March 23, 2026, with a Neutral rating and a $1.50 price target, indicating a cautious outlook due to competitive pressures that may limit upside potential.
- Clinical Data Update: On January 8, 2026, Jasper reported updated data for briquilimab, revealing that 67% of patients achieved a complete response at 12 weeks, while 83% responded by week 3 after the initial dose, highlighting the therapy's promise in chronic spontaneous urticaria (CSU).
- Future Research Plans: The company plans to initiate a Phase 2b study for CSU in the second half of 2026, with BEACON and open-label extension data supporting dose selection, demonstrating positive progress in clinical development.
- Investment Outlook Analysis: While Jasper is viewed as a potential investment, UBS noted that certain AI stocks offer greater upside potential and lower downside risk, reflecting a shift in market preference towards more attractive investment options in the biotech sector.
See More
UBS Initiates Coverage of Jasper Therapeutics Inc with Neutral Rating and $1.50 Price Target
Company Overview: Jaspar Therapeutics is a biopharmaceutical company focused on developing innovative therapies.
Recent Coverage: The company has received neutral ratings in recent analyses, indicating a cautious outlook from analysts.
Target Price: Analysts have set a target price of $1.50 for Jaspar Therapeutics' stock.
Market Position: The neutral rating suggests that while there is potential, there are also risks that investors should consider.
See More
Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment
- Leadership Change: Jasper Therapeutics has appointed Jeet Mahal as CEO, succeeding Ronald Martell, who joined in 2022; Mahal brings over 30 years of life sciences experience and will drive the development of briquilimab, enhancing the company's competitiveness in chronic urticaria.
- Clinical Research Update: Jasper will host an investor webinar on January 8, 2026, to present updated data from the BEACON study and open-label extension studies, aiming to boost investor confidence and increase focus on briquilimab.
- Product Development Strategy: Mahal emphasized briquilimab's potential in chronic spontaneous urticaria and inducible urticaria, planning to efficiently complete current studies and lay the groundwork for future development, which is expected to provide more effective treatment options for patients.
- Former CEO Contributions: Ronald Martell successfully pivoted briquilimab's development towards allergic and immunological diseases during his tenure, establishing a foundation for clinical proof of concept that supports the company's future growth.
See More
